Skip to main content
Chabiotech Co.,Ltd. logo

Chabiotech Co.,Ltd. — Investor Relations & Filings

Ticker · 085660 ISIN · KR7085660009 KO Professional, scientific and technical activities
Open in API
Filings indexed 460 across all filing types
Latest filing 2023-03-16 AGM Information
Country KR South Korea
Listing KO 085660

About Chabiotech Co.,Ltd.

http://en.chabio.com/

Chabiotech Co., Ltd. is a biotechnology company specializing in the research and development of cell and gene therapies for rare cancers and incurable diseases. The company's core activities include advancing its therapeutic pipelines and providing global Contract Development and Manufacturing Organization (CDMO) services for advanced biopharmaceuticals, including full-scale GMP production and testing. Chabiotech also operates bio-banking services, such as cord blood and immune/stem cell storage, utilizing advanced cryopreservation technology. Its diversified business segments extend to genomics for precision medicine, healthcare IT solutions that integrate AI and Big Data, comprehensive wellness programs, and specialized healthcare consulting.

Recent filings

Filing Released Lang Actions
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal regulatory filing submitted by CHA Biotech to the KOSDAQ exchange. It explains the company's decision to hold its Annual General Meeting (AGM) on a 'concentrated date' (a date when many companies hold their AGMs), which is a specific regulatory disclosure requirement in the Korean market. Since it does not contain the actual AGM presentation materials, voting results, or proxy materials, but rather serves as a regulatory notification regarding the scheduling of the meeting, it falls under the general regulatory filing category.
2023-03-16 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of Convocation of the Annual General Meeting' (주주총회소집공고) for Cha Biotech. It contains the meeting date, location, agenda items (financial statement approval, director appointments, etc.), and information regarding electronic voting. This document is a formal proxy statement and meeting notice sent to shareholders to solicit their participation and votes for the upcoming AGM. According to the provided filing definitions, this falls under 'Proxy Solicitation & Information Statement'.
2023-03-16 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Proxy Solicitation & Information Statement' (의결권대리행사권유참고서류) issued by CHA Biotech. It contains detailed information regarding the upcoming Annual General Meeting (AGM), including the purpose of the solicitation, the solicitor's details, the agenda items (such as approval of financial statements, appointment of directors/auditors, and remuneration limits), and instructions for shareholders to exercise their voting rights via electronic or written proxy. This aligns perfectly with the definition of a Proxy Solicitation & Information Statement (PSI).
2023-03-16 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Cha Biotech) announcing a significant change in financial results (revenue or profit/loss structure exceeding 15% for large corporations or 30% for others). This is a standard disclosure requirement in the Korean stock market (KRX) for material financial changes. Since it provides the initial announcement of financial performance figures before the final audit report is finalized, it falls under the 'Earnings Release' category. FY 2022
2023-03-02 Korean
투자판단관련주요경영사항(AMD(노인성 황반변성) 치료제 국내 임상 1/2a상 조기 종료)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Cha Biotech regarding the early termination of a clinical trial (AMD treatment). It is a formal disclosure of a material management event, which is a standard regulatory announcement in the Korean market (KIND system). Since it does not fit into specific categories like M&A, dividends, or financial reports, it falls under the general regulatory filing category.
2023-03-02 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% report). It details the shareholding status of major shareholders and their special related parties, including changes in collateral agreements. This falls under the category of Major Shareholding Notification (MRQ).
2023-02-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.